“Dual receptor agonism is both additive and complementary, Dr. Green explained. GLP-1 activity reduces food intake, improves insulin secretion, reduces glucagon secretion, and delays gastric emptying. GIP activity also reduces food intake and improves beta cell function while improving insulin sensitivity and nutrient metabolism.
Dual incretin receptor agonism also brings important renal benefits and, at a minimum, carries no increased cardiovascular risk. Cardiovascular benefits are still in trial. The renal benefits alone are a dramatic improvement over existing management options.”
From:
Trials indicate incretin therapy can prevent and better manage type 2 diabetes
ADA Meeting News, August 2022
“The results show tirzepatide participants experienced fewer renal complications, compared to those that received insulin. In particular, the rates of new onset of macroalbuminuria, a signal of poor renal outcomes, were significantly lower in the tirzepatide arm (Hazard Ratio = 0.41). Additionally, in individuals with type 2 diabetes and high cardiovascular risk, tirzepatide reduced the rate of kidney function loss and the amount of urinary protein excretion, a risk marker for progression of CKD.”
Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk
American Diabetes Association press release, June 2022